A suicide gene approach using the human pro-apoptotic protein tBid inhibits HIV-1 replication

Peter M Huelsmann1, Andreas D Hofmann, Stefanie A Knoepfel

  • 1University of Erlangen-Nuremberg, Institute of Clinical and Molecular Virology, Erlangen, Germany.

BMC Biotechnology
|January 13, 2011
PubMed
Abstract

Insights

This study introduces a novel suicide gene therapy for HIV-1. The truncated Bid (tBid) gene effectively eliminates HIV-1 infected cells by inducing rapid apoptosis, offering a promising new treatment strategy.

Area of Science:

  • Gene therapy
  • Virology
  • Molecular biology

Background:

  • Suicide gene therapy offers a method for targeted cell elimination.
  • Eliminating human immunodeficiency virus type 1 (HIV-1) infected cells is a key therapeutic goal.
  • Previous suicide gene approaches for HIV-1 have been limited by gene efficacy and specificity.

Purpose of the Study:

  • To evaluate truncated Bid (tBid) as a suicide gene for HIV-1 gene therapy.
  • To assess the efficacy and specificity of tBid in eliminating HIV-1 infected cells.

Main Methods:

  • Constructed an HIV-1 LTR-based suicide gene expression vector (pLRed(INS)2R) encoding tBid.
  • Tested the vector's ability to induce apoptosis in cells expressing HIV-1 regulatory proteins Tat and Rev.
  • Assessed the impact of the vector on HIV-1 replication in infected cells.

Main Results:

  • The tBid suicide vector efficiently induced apoptosis within 24 hours, exclusively in the presence of HIV-1 Tat and Rev proteins.
  • Cells transfected with the vector and HIV-1 genomic DNA showed complete elimination, preventing viral replication.
  • HIV-1 particle infection of cells containing the vector showed a significant reduction in viral replication.

Conclusions:

  • The developed suicide vector demonstrates potential for safe and effective gene therapy against HIV-1.
  • This approach targets the exclusive elimination of HIV-1 infected cells prior to infectious virus release.
  • tBid represents a potent suicide gene for combating HIV-1 infection.